← Back to Screener
Keros Therapeutics, Inc. Common Stock (KROS)
Price$10.30
Value ScoreA
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-49.00%
Price vs S&P 500 (4W)-14.65%
VGM Score39.63
Market Capitalization$203.86M
P/E Ratio (Annual)2.34x
All Metrics
P/CF (Annual)1.90x
Book Value / Share (Quarterly)$14.47
P/TBV (Annual)3.32x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-43.89%
Cash Flow / Share (Quarterly)$-2.95
Price vs S&P 500 (YTD)-57.57%
Net Profit Margin (TTM)-256.60%
EPS (TTM)$-3.01
10-Day Avg Trading Volume0.24M
EPS Excl Extra (TTM)$-3.01
Revenue Growth (5Y)-18.71%
EPS (Annual)$2.30
ROI (Annual)28.70%
Net Profit Margin (5Y Avg)-21395.35%
Cash / Share (Quarterly)$14.27
P/E Basic Excl Extra (TTM)2.55x
Revenue Growth QoQ (YoY)-99.83%
P/E Normalized (Annual)2.34x
ROA (Last FY)25.74%
Revenue Growth TTM (YoY)-84.55%
EBITD / Share (TTM)$-3.40
ROE (5Y Avg)-22.40%
Operating Margin (TTM)-332.55%
Cash Flow / Share (Annual)$5.42
P/B Ratio0.71x
P/B Ratio (Quarterly)0.76x
Net Income / Employee (Annual)$1,115,600
EV / Revenue (TTM)-2.34x
Net Interest Coverage (TTM)-4552.00x
ROA (TTM)-15.84%
EV / EBITDA (TTM)-1.12x
EPS Incl Extra (Annual)$2.30
Current Ratio (Annual)15.45x
Quick Ratio (Quarterly)22.25x
3-Month Avg Trading Volume0.38M
52-Week Price Return-31.83%
EV / Free Cash Flow (Annual)-0.73x
P/E Incl Extra (TTM)2.55x
Revenue / Employee (TTM)$425,400
Tangible BV / Share (Quarterly)$9.97
P/S Ratio (Annual)0.84x
Asset Turnover (Annual)0.72x
52-Week High$22.55
Operating Margin (5Y Avg)-23768.21%
EPS Excl Extra (Annual)$2.30
CapEx CAGR (5Y)39.84%
26-Week Price Return-41.08%
Quick Ratio (Annual)15.22x
13-Week Price Return-12.04%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.62x
Enterprise Value$-77.64M
Revenue / Share Growth (5Y)-28.88%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)6.58%
Revenue / Employee (Annual)$3,129,000
Pretax Margin (Annual)37.65%
Cash / Share (Annual)$14.71
3-Month Return Std Dev58.74%
Net Income / Employee (TTM)$-1,091,600
ROE (Last FY)28.70%
Net Interest Coverage (Annual)-114790.00x
EPS Basic Excl Extra (Annual)$2.30
Receivables Turnover (TTM)3.75x
EV / Free Cash Flow (TTM)-0.62x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.01
Receivables Turnover (Annual)77.37x
ROI (TTM)-17.04%
P/S Ratio (TTM)6.14x
Pretax Margin (5Y Avg)-21391.26%
Revenue / Share (Annual)$6.45
Tangible BV / Share (Annual)$10.07
Forward P/E6.37x
Price vs S&P 500 (52W)-56.20%
P/E Ratio (TTM)2.55x
Year-to-Date Return-49.41%
5-Day Price Return-5.50%
EPS Normalized (Annual)$2.30
ROA (5Y Avg)-20.63%
Net Profit Margin (Annual)35.65%
Month-to-Date Return-8.44%
Cash Flow / Share (TTM)$-4.93
EBITD / Share (Annual)$1.82
Operating Margin (Annual)27.69%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)2.07x
ROI (5Y Avg)-22.40%
P/E Excl Extra (TTM)2.55x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.01
P/TBV (Quarterly)3.12x
P/B Ratio (Annual)2.05x
Pretax Margin (TTM)-272.15%
Book Value / Share (Annual)$15.51
Price vs S&P 500 (13W)-20.30%
Beta1.00x
P/FCF (Annual)1.92x
Revenue / Share (TTM)$1.69
ROE (TTM)-17.04%
52-Week Low$9.79
vGradeA
gGradeF
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-1.21est. -1.04
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.93
3.93
3.93
3.86
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KROSKeros Therapeutics, Inc. Common Stock | A | F | D | $10.30 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel protein therapeutics for blood disorders with significant unmet needs. The company's lead program, KER-050, targets cytopenias—including anemia and thrombocytopenia—in patients with myelodysplastic syndromes and myelofibrosis.